DDInter1881 DDInter1666
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment for angina - or chest pain associated with inadequate blood flow to the heart - before being serendipitously indicated for treating erectile dysfunction in the late 1980s . Nevertheless, it is because of this mechanism that sildenafil is also indicated for treating pulmonary arterial hypertension but is also additionally notorious for interacting with various anti-anginal or anti-hypertensive agents to develop potentially rapid, excessive, and/or fatal hypotensive crises [A175579, A175582, A175654]. Regardless, sildenafil, among a variety of other similar or related PDE5 inhibitors, has become a common and effective treatment for erectile dysfunction and since its formal approval for medical use in the public in 1998 , continues to see millions of prescriptions written for it internationally. Although the medication has historically been most popularly recognized as Pfizer's brand name Viagra, sildenafil is currently available generically and even as a non-prescription over the counter medication in some countries .
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Sildenafil
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Dolutegravir {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Sildenafil
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dofetilide
Dofetilide {u} (Compound) downregulates {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Sildenafil
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Goserelin {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Sildenafil
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Ramelteon {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sildenafil
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Goserelin
Goserelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vardenafil
Vardenafil {u} (Compound) resembles {v} (Compound) Sildenafil
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Sildenafil
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Ramelteon {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Sildenafil
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vardenafil
Vardenafil {u} (Compound) resembles {v} (Compound) Sildenafil
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etacrynic acid
Etacrynic acid {u} (Compound) downregulates {v} (Gene) CYCS
CYCS {u} (Gene) is downregulated by {v} (Compound) Sildenafil
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Sildenafil (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sildenafil (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Dofetilide and Dofetilide (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Sildenafil (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sildenafil (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon and Ramelteon (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sildenafil (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil and Vardenafil (Compound) resembles Sildenafil (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Sildenafil (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon and Ramelteon (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Sildenafil (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vardenafil and Vardenafil (Compound) resembles Sildenafil (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Sildenafil (Compound)